Easier abacavir regimen has promising results.
HIV patients, understandably, are sometimes unenthusiastic about taking their protease inhibitor (PI) drug therapies because of the numerous pills, the side effects, and chronic problems such as lipodystrophy. To address these problems, researchers have been studying non-PI drug therapies that are potent against HIV. Research has demonstrated successful viral suppression for at least 24 weeks when patients were switched from a PI regimen to an abacavir regimen.
D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D010349:Patient Compliance; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load; D000099227:Abacavir
D015224:Dideoxynucleosides; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir